These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7627705)

  • 1. Tissue factor pathway inhibitor activity associated with LDL is inactivated by cell- and copper-mediated oxidation.
    Lesnik P; Dentan C; Vonica A; Moreau M; Chapman MJ
    Arterioscler Thromb Vasc Biol; 1995 Aug; 15(8):1121-30. PubMed ID: 7627705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the inhibitory effects of ApoB100 and tissue factor pathway inhibitor on tissue factor and the influence of lipoprotein oxidation.
    Ettelaie C; Wilbourn BR; Adam JM; James NJ; Bruckdorfer KR
    Arterioscler Thromb Vasc Biol; 1999 Jul; 19(7):1784-90. PubMed ID: 10397699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PAF-acether-degrading acetylhydrolase in plasma LDL is inactivated by copper- and cell-mediated oxidation.
    Dentan C; Lesnik P; Chapman MJ; Ninio E
    Arterioscler Thromb; 1994 Mar; 14(3):353-60. PubMed ID: 8123638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue factor pathway inhibitor is expressed by human monocyte-derived macrophages : relationship to tissue factor induction by cholesterol and oxidized LDL.
    Petit L; Lesnik P; Dachet C; Moreau M; Chapman MJ
    Arterioscler Thromb Vasc Biol; 1999 Feb; 19(2):309-15. PubMed ID: 9974412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effects of LDL-associated tissue factor pathway inhibitor.
    Augustsson C; Hilden I; Petersen LC
    Thromb Res; 2014 Jul; 134(1):132-7. PubMed ID: 24787991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of leukocyte elastase on tissue factor pathway inhibitor.
    Higuchi DA; Wun TC; Likert KM; Broze GJ
    Blood; 1992 Apr; 79(7):1712-9. PubMed ID: 1558967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces.
    Hamamoto T; Yamamoto M; Nordfang O; Petersen JG; Foster DC; Kisiel W
    J Biol Chem; 1993 Apr; 268(12):8704-10. PubMed ID: 8473315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a).
    Lesnik P; Vonica A; Guérin M; Moreau M; Chapman MJ
    Arterioscler Thromb; 1993 Jul; 13(7):1066-75. PubMed ID: 8318508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the C-terminal domain in the inhibitory functions of tissue factor pathway inhibitor.
    Ettelaie C; Adam JM; James NJ; Oke AO; Harrison JA; Bunce TD; Bruckdorfer KR
    FEBS Lett; 1999 Dec; 463(3):341-4. PubMed ID: 10606750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue factor residues Lys165 and Lys166 are essential for rapid formation of the quaternary complex of tissue factor.VIIa with Xa.tissue factor pathway inhibitor.
    Rao LV; Ruf W
    Biochemistry; 1995 Aug; 34(34):10867-71. PubMed ID: 7662667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro.
    Hansen JB; Huseby KR; Huseby NE; Ezban M; Nordøy A
    Thromb Res; 1997 Mar; 85(5):413-25. PubMed ID: 9076898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of the inhibition of factor Xa and the tissue factor-factor VIIa complex by the tissue factor pathway inhibitor in the presence and absence of heparin.
    Jesty J; Wun TC; Lorenz A
    Biochemistry; 1994 Oct; 33(42):12686-94. PubMed ID: 7918495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of secreted Kunitz domain 1 variants of tissue factor pathway inhibitor.
    Johnson K; Zaror I; Bauer D; Choi Y; Creasey A; Innis M
    Thromb Haemost; 1998 Oct; 80(4):585-7. PubMed ID: 9798974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of porcine endothelial tissue factor pathway inhibitor on human coagulation factors.
    Kopp CW; Siegel JB; Hancock WW; Anrather J; Winkler H; Geczy CL; Kaczmarek E; Bach FH; Robson SC
    Transplantation; 1997 Mar; 63(5):749-58. PubMed ID: 9075849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor.
    Hamamoto T; Kisiel W
    Blood Coagul Fibrinolysis; 1996 Jun; 7(4):470-6. PubMed ID: 8840000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidized low-density lipoprotein impairs the anti-coagulant function of tissue-factor-pathway inhibitor through oxidative modification by its high association and accelerated degradation in cultured human endothelial cells.
    Horie S; Hiraishi S; Hirata Y; Kazama M; Matsuda J
    Biochem J; 2000 Dec; 352 Pt 2(Pt 2):277-85. PubMed ID: 11085919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Localization of tissue factor pathway inhibitor to lipid rafts is not required for inhibition of factor VIIa/tissue factor activity.
    Dietzen DJ; Jack GG; Page KL; Tetzloff TA; Hall CL; Mast AE
    Thromb Haemost; 2003 Jan; 89(1):65-73. PubMed ID: 12540955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor.
    Lindhout T; Franssen J; Willems G
    Thromb Haemost; 1995 Sep; 74(3):910-5. PubMed ID: 8571320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias.
    Zitoun D; Bara L; Basdevant A; Samama MM
    Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):77-81. PubMed ID: 8548430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidized phospholipids in oxidized low-density lipoprotein reduce the activity of tissue factor pathway inhibitor through association with its carboxy-terminal region.
    Ohkura N; Hiraishi S; Itabe H; Hamuro T; Kamikubo Y; Takano T; Matsuda J; Horie S
    Antioxid Redox Signal; 2004 Aug; 6(4):705-12. PubMed ID: 15242551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.